Skip to main content


Independent Education Session

Rethinking Glioblastoma Care in an Evolving Therapeutic Landscape: Expert Perspectives on Modern Modalities, Novel Agents, and Combinations 

Register For Webinar

Chair & Presenter
Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Manmeet Ahluwalia, MD, FACP, MBA
Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, Ohio

Steven A. Toms, MD, MPH, FAANS, FACS
LPG Neurosurgery-Norman Prince Neuroscience Institute
Lifespan Physician Group, Inc.
The Warren Alpert Medical School of Brown University
Providence, Rhode Island

Activity Description
As new therapeutic strategies are explored and validated, oncologists have more effective treatments to offer their patients with glioblastoma, the most common and lethal brain tumor in adults. Tumor treating fields (TTFields), a novel modality, has been an important step forward in improving outcomes in glioblastoma and has increased the armamentarium beyond surgical resection, radiation therapy, and chemotherapy. Moreover, targeted therapies continue to demonstrate promising results. Join PeerView and the American Brain Tumor Association to learn about the latest evidence on TTFields and other treatment strategies, including targeted therapies, such as antiangiogenic antibodies and multikinase and TRK inhibitors, that are being explored in glioblastoma. In this CME-certified web broadcast, a panel of experts in neuro-oncology will provide insights on the future of glioblastoma management, strategies for integrating therapeutic advances into the clinic, and approaches to personalizing care, including the considerations of clinical trial enrollment, for patients with glioblastoma.

Welcome and Introduction
Seminar and Practicum 1: Effectively Integrating Modern Modalities and Systemic Therapies in the Management of Glioblastoma
Seminar and Practicum 2: A Bright Outlook With Novel Systemic Options for Patients With Glioblastoma
Symposium Summary and Audience Q&A

Support Statement
This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc., Karyopharm Therapeutics, Inc., and Novocure.
Provider Statement
This CE activity is jointly provided by Medical Learning Institute, Inc., the American Brain Tumor Association, and PVI, PeerView Institute for Medical Education.
The Society for Neuro-Oncology has reviewed and approved this web broadcast as appropriate for presentation as an independent educational session. The web broadcast constitutes the content and views of the provider and is not part of the official SNO Annual Meeting program.